Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...